10 research outputs found
Optimised oligonucleotide substrates to assay XPF ERCC1 nuclease activity for the discovery of DNA repair inhibitors
We report the design and optimisation of novel oligonucleotide substrates for a sensitive fluorescence assay for high-throughput screening and functional studies of the DNA repair enzyme, XPF-ERCC1, with a view to accelerating inhibitor and drug discover
Understanding the role of RNA nucleases in human disease
Congenital dyserythropoietic anaemia type-I (CDA-I) is a rare inherited disorder of erythropoiesis, in which patient erythroblasts uniquely display a pathognomonic pattern of heterochromatin, referred to as âspongyâ heterochromatin. The molecular basis of CDA-I remains unknown. Most cases of CDA-I are caused by mutations in a protein of unknown function, termed Codanin-1. However, the recent identification of a second disease gene in CDA-I, namely C15orf41, has marked a breakthrough in providing new insights into CDA-I. This study describes the previously-uncharacterised protein C15orf41 as a novel RNA exonuclease that associates in vivo and in vitro with Codanin-1. Using the newly generated CDA-I disease model in an erythroid-specific HUDEP-2 cell background, C15orf41 and Codanin-1 complex formation is determined at physiologically relevant levels. This interaction is then also confirmed in vitro. The C15orf41-Codanin-1 complex is a versatile RNA nuclease complex, able to digest a variety of RNA structures. We also show the association and nucleolytic activity of C15orf41-Codanin-1 are disrupted by the introduction of CDA-I patient mutations p. Y94C and p. L178Q in C15orf41. This suggests a direct link between the disease phenotype observed and C15orf41âs novel RNAse activity, a potential new target for alternative treatment development.
In light of the 2020 SARS-CoV-2 global pandemic, the focus of this study was broadened to perform essential research on the SARS-CoV-2 virus, in particular the nsp14-nsp10 RNA nuclease complex. This work provides the first complete biochemical activity report for the SARS-CoV-2 nsp14-nsp10 complex, characterising its exonuclease activity as well as a identifying a novel, endonuclease activity. These results have served as a basis for inhibitor development and screening, essential considering the global health impact of this virus.</p
RPA activates the XPFâERCC1 endonuclease to initiate processing of DNA interstrand crosslinks
During replicationâcoupled DNA interstrand crosslink (ICL) repair, the XPFâERCC1 endonuclease is required for the incisions that release, or âunhookâ, ICLs, but the mechanism of ICL unhooking remains largely unknown. Incisions are triggered when the nascent leading strand of a replication fork strikes the ICL. Here, we report that while purified XPFâERCC1 incises simple ICLâcontaining model replication fork structures, the presence of a nascent leading strand, modelling the effects of replication arrest, inhibits this activity. Strikingly, the addition of the singleâstranded DNA (ssDNA)âbinding replication protein A (RPA) selectively restores XPFâERCC1 endonuclease activity on this structure. The 5âČâ3âČ exonuclease SNM1A can load from the XPFâERCC1âRPAâinduced incisions and digest past the crosslink to quantitatively complete the unhooking reaction. We postulate that these collaborative activities of XPFâERCC1, RPA and SNM1A might explain how ICL unhooking is achieved in vivo
RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks.
During replication-coupled DNA interstrand crosslink (ICL) repair, the XPF-ERCC1 endonuclease is required for the incisions that release, or "unhook", ICLs, but the mechanism of ICL unhooking remains largely unknown. Incisions are triggered when the nascent leading strand of a replication fork strikes the ICL Here, we report that while purified XPF-ERCC1 incises simple ICL-containing model replication fork structures, the presence of a nascent leading strand, modelling the effects of replication arrest, inhibits this activity. Strikingly, the addition of the single-stranded DNA (ssDNA)-binding replication protein A (RPA) selectively restores XPF-ERCC1 endonuclease activity on this structure. The 5'-3' exonuclease SNM1A can load from the XPF-ERCC1-RPA-induced incisions and digest past the crosslink to quantitatively complete the unhooking reaction. We postulate that these collaborative activities of XPF-ERCC1, RPA and SNM1A might explain how ICL unhooking is achieved in vivo
RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks.
During replication-coupled DNA interstrand crosslink (ICL) repair, the XPF-ERCC1 endonuclease is required for the incisions that release, or "unhook", ICLs, but the mechanism of ICL unhooking remains largely unknown. Incisions are triggered when the nascent leading strand of a replication fork strikes the ICL Here, we report that while purified XPF-ERCC1 incises simple ICL-containing model replication fork structures, the presence of a nascent leading strand, modelling the effects of replication arrest, inhibits this activity. Strikingly, the addition of the single-stranded DNA (ssDNA)-binding replication protein A (RPA) selectively restores XPF-ERCC1 endonuclease activity on this structure. The 5'-3' exonuclease SNM1A can load from the XPF-ERCC1-RPA-induced incisions and digest past the crosslink to quantitatively complete the unhooking reaction. We postulate that these collaborative activities of XPF-ERCC1, RPA and SNM1A might explain how ICL unhooking is achieved in vivo
Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification
Abstract The SARS-CoV-2 coronavirus (CoV) causes COVID-19, a current global pandemic. SARS-CoV-2 belongs to an order of Nidovirales with very large RNA genomes. It is proposed that the fidelity of CoV genome replication is aided by an RNA nuclease complex, formed of non-structural proteins 14 and 10 (nsp14-nsp10), an attractive target for antiviral inhibition. Here, we confirm that the SARS-CoV-2 nsp14-nsp10 complex is an RNase. Detailed functional characterisation reveals nsp14-nsp10 is a highly versatile nuclease capable of digesting a wide variety of RNA structures, including those with a blocked 3’-terminus. We propose that the role of nsp14-nsp10 in maintaining replication fidelity goes beyond classical proofreading and purges the nascent replicating RNA strand of a range of potentially replication terminating aberrations. Using the developed assays, we identify a series of drug and drug-like molecules that potently inhibit nsp14-nsp10, including the known Sars-Cov-2 major protease (M pro ) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the potential for bifunctional inhibitors in the treatment of COVID-19
Characterization of the SARS-CoV-2 ExoN (nsp14ExoNânsp10) complex: implications for its role in viral genome stability and inhibitor identification
The SARS-CoV-2 coronavirus is the causal agent of the current global pandemic. SARS-CoV-2 belongs to an order, Nidovirales, with very large RNA genomes. It is proposed that the fidelity of coronavirus (CoV) genome replication is aided by an RNA nuclease complex, comprising the non-structural proteins 14 and 10 (nsp14ânsp10), an attractive target for antiviral inhibition. Our results validate reports that the SARS-CoV-2 nsp14ânsp10 complex has RNase activity. Detailed functional characterization reveals nsp14ânsp10 is a versatile nuclease capable of digesting a wide variety of RNA structures, including those with a blocked 3âČ-terminus. Consistent with a role in maintaining viral genome integrity during replication, we find that nsp14ânsp10 activity is enhanced by the viral RNA-dependent RNA polymerase complex (RdRp) consisting of nsp12ânsp7ânsp8 (nsp12â7â8) and demonstrate that this stimulation is mediated by nsp8. We propose that the role of nsp14ânsp10 in maintaining replication fidelity goes beyond classical proofreading by purging the nascent replicating RNA strand of a range of potentially replication-terminating aberrations. Using our developed assays, we identify drug and drug-like molecules that inhibit nsp14ânsp10, including the known SARS-CoV-2 major protease (Mpro) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the potential for multifunctional inhibitors in COVID-19 treatment
Genetic and functional insights into CDA-I prevalence and pathogenesis
Background Congenital dyserythropoietic anaemia type I (CDA-I) is a hereditary anaemia caused by biallelic mutations in the widely expressed genes CDAN1 and C15orf41. Little is understood about either protein and it is unclear in which cellular pathways they participate.
Methods Genetic analysis of a cohort of patients with CDA-I identifies novel pathogenic variants in both known causative genes. We analyse the mutation distribution and the predicted structural positioning of amino acids affected in Codanin-1, the protein encoded by CDAN1. Using western blotting, immunoprecipitation and immunofluorescence, we determine the effect of particular mutations on both proteins and interrogate protein interaction, stability and subcellular localisation.
Results We identify six novel CDAN1 mutations and one novel mutation in C15orf41 and uncover evidence of further genetic heterogeneity in CDA-I. Additionally, population genetics suggests that CDA-I is more common than currently predicted. Mutations are enriched in six clusters in Codanin-1 and tend to affect buried residues. Many missense and in-frame mutations do not destabilise the entire protein. Rather C15orf41 relies on Codanin-1 for stability and both proteins, which are enriched in the nucleolus, interact to form an obligate complex in cells.
Conclusion Stability and interaction data suggest that C15orf41 may be the key determinant of CDA-I and offer insight into the mechanism underlying this disease. Both proteins share a common pathway likely to be present in a wide variety of cell types; however, nucleolar enrichment may provide a clue as to the erythroid specific nature of CDA-I. The surprisingly high predicted incidence of CDA-I suggests that better ascertainment would lead to improved patient care.</p
Genetic and functional insights into CDA-I prevalence and pathogenesis.
Congenital dyserythropoietic anaemia type I (CDA-I) is a hereditary anaemia caused by biallelic mutations in the widely expressed genes CDAN1 and C15orf41. Little is understood about either protein and it is unclear in which cellular pathways they participate.
Genetic analysis of a cohort of patients with CDA-I identifies novel pathogenic variants in both known causative genes. We analyse the mutation distribution and the predicted structural positioning of amino acids affected in Codanin-1, the protein encoded by CDAN1. Using western blotting, immunoprecipitation and immunofluorescence, we determine the effect of particular mutations on both proteins and interrogate protein interaction, stability and subcellular localisation.
We identify six novel CDAN1 mutations and one novel mutation in C15orf41 and uncover evidence of further genetic heterogeneity in CDA-I. Additionally, population genetics suggests that CDA-I is more common than currently predicted. Mutations are enriched in six clusters in Codanin-1 and tend to affect buried residues. Many missense and in-frame mutations do not destabilise the entire protein. Rather C15orf41 relies on Codanin-1 for stability and both proteins, which are enriched in the nucleolus, interact to form an obligate complex in cells.
Stability and interaction data suggest that C15orf41 may be the key determinant of CDA-I and offer insight into the mechanism underlying this disease. Both proteins share a common pathway likely to be present in a wide variety of cell types; however, nucleolar enrichment may provide a clue as to the erythroid specific nature of CDA-I. The surprisingly high predicted incidence of CDA-I suggests that better ascertainment would lead to improved patient care